The Patent Finder
FP

Fusion Pharmaceuticals Inc.

First filing 2016
OverviewNotableFeesChangesFamiliesPatent listSources & methods

One patent currently held, every record listed here

1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.

The next term ends in Dec 2039. from the record

Of the 1 now held by other companies, 1 name Centre for Probe Development and Commercialization as their current owner. Each row says so.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Dec 2039
Next term end
1
Patent families

When these terms end

Each bar runs from grant to computed term end. 2021 to 2039.
US 11,191,854 Pharmacokinetic Enhancements of Bifunctional Chelates and Uses Thereof no later than May 4, 2038
US 11,446,401 ACTINIUM-225 and Checkpoint Inhibitor Combination Therapy Dec 3, 2039
20252029203320372039
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
18 pending applications: term is not computable until grant.Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.

Formerly held, still cited

Notable
Granted 2021. Computed term ends 2038. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Ends no later than May 2038 · Medium confidence

Fee deadlines

No maintenance fee falls due on this company's record before Nov 10, 2027.

Recent changes

  • 1 term has ended since Aug 17, 2026

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 1 of 1

PatentTitleStatusExpiresConfidence
US 11,446,401ACTINIUM-225 and Checkpoint Inhibitor Combination Therapy
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 1: 1 patent in force now held by others · 2 patents ended · 18 applications pending · 19 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited